FRM
RXRX icon

Fox Run Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Fox Run Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-59,525
Closed -$315K – 1177
2025
Q1 		$315K Buy
59,525
+28,447
+92% +$207K 0.05% 658
2024
Q4 		$210K Buy
+31,078
New +$209K 0.04% 745
2024
Q3 		– Sell
-12,311
Closed -$92.3K – 1064
2024
Q2 		$92.3K Sell
12,311
-1,758
-12% -$15.3K 0.02% 727
2024
Q1 		$140K Buy
+14,069
New +$157K 0.03% 682
2023
Q3 		– Sell
-18,917
Closed -$141K – 955
2023
Q2 		$141K Buy
18,917
+2,183
+13% +$15.3K 0.04% 619
2023
Q1 		$112K Buy
+16,734
New +$133K 0.04% 592

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Fox Run Management's RXRX Position: Q2 2025 in Review

Fox Run Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2025, closing a stake of 59,525 shares — an estimated $315K sold.

Fox Run Management first reported a position in RXRX in Q1 2023 and held it in 6 quarters. The position peaked at $315K in Q1 2025. 332 funds tracked by Wall St. Rank hold RXRX as of Q2 2025.

  • Fox Run Management reported no remaining Recursion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Fox Run Management sold 59,525 Recursion Pharmaceuticals shares in Q2 2025, an estimated $315K.
  • Fox Run Management first reported a position in Recursion Pharmaceuticals in Q1 2023 and held it in 6 quarters.
  • Fox Run Management's Recursion Pharmaceuticals position peaked at $315K in Q1 2025.
  • 332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2025.

Based on Fox Run Management's 13F filing for Q2 2025, filed 6 Aug 2025.